Dhipatimendi rePasi Pose

Musi wa20 Nyamavhuvhu 2025, Abbisko Therapeutics yakazivisa kuti Center forDrug Evaluation (CDE) yeChina National Medical Products Administration (NlPA) yakabvumidza chikumbiro cheLND cheAbbisko's investigative oral PD-1 inhibitor, ABSK043, pamwe chete neShanghai Alist Pharmaceuticals KRAS ...Verenga zvakawanda»

Munguva pfupi yapfuura, chidzidzo cheAntengene's Phase I/II CLINCH cheATG-022 (CLDN18.2 antibody-drug conjugate), murwere akwegura ane kenza yemudumbu yakakwira uyo akafambira mberi pakurapa mishonga yakawanda, immunotherapy uye targeted therapy kunyangwe metastases yakakura yakawana mhinduro yakakwana (CR) ...Verenga zvakawanda»

Musi wa13 Nyamavhuvhu, 2025, Pacific Time, webhusaiti yepamutemo ye2025 World Conference on Lung Cancer (WCLC) yakaburitsa zvidimbu zvekutsvagisa zvakasarudzwa zvemusangano wegore rino, Pakati pezvakakosha pane chidimbu chakagadziridzwa chekuyedzwa kwekutanga kwekiriniki yePhase 1 yeHLX43, Henlius' PD-L1 ADC. A...Verenga zvakawanda»

Musi wa7 Nyamavhuvhu, Center for Drug Evaluation (CDE) yeNational Medical Products Administration (NMPA) yakazivisa kuti jekiseni rePA3-17 rakapihwa kuti ribatanidzwe muchirongwa chekurapa kwekubudirira, chakagadzirirwa kurapa varwere vakuru vane relapse/refractory T-cell acute lymph...Verenga zvakawanda»

Musi wa11 Nyamavhuvhu, Center for Drug Evaluation (CDE) yeNational Medical Products Administration (NMPA) yakaratidza kuti kushandiswa kweInxMed kwemapiritsi eIN10018 kwakakurudzirwa kuti kushandiswe pakurapa kwepakutanga, kwakagadzirirwa kusanganiswa neD-1553 kurapa KRA yepamusoro kana kuti yakapararira munharaunda...Verenga zvakawanda»

VaX murwere ari mumakore ake ekuma40 akaonekwa aine acral melanoma. Mushure mekuvhiyiwa zvakanyanya mushure mekuongororwa muna 2015, mamiriro avo akaramba akasimba kwemakore mapfumbamwe. Zvinosuwisa kuti, gore rapfuura, chirwere chavo chakadzokazve nemetastases mumapapu ese ari maviri. Kunyangwe vakabatwa negomarara remuromo wegumbo nerechiuno...Verenga zvakawanda»

Musi wa31 Chikunguru, AstraZeneca neMerck & Co. vakazivisa pamwe chete kuti mushonga wavo wePARP inhibitor Lynparza, pamwe chete neAbiraterone neprednisolone, wabvumidzwa muChina kurapa varwere vakuru vane metastatic castration-resistant prostate cancer (mCRPC) vane germline kana zvimwe zvirwere...Verenga zvakawanda»

Musi wa31 Chikunguru, 2025, ImmuneOnco Biopharmaceuticals yakazivisa data rekutanga rekuchengetedza uye kushanda zvakanaka kubva kuongororo yePhase 2 yakavhurika, ine nzvimbo dzakawanda dzekudzidza kweIMM2510 pamwe chete nechemotherapy yevarwere vari pamberi vane kenza yemapapu isiri diki (NSCLC) yakaitwa muChina. Kubva musi wa1 Chikunguru, 2025,...Verenga zvakawanda»

Musi wa30 Chikunguru, National Medical Products Administration (NMPA) yakabvumidza zviri pamutemo kutengeswa kweHICARA yekurapa varwere vakuru vane relapse or refractory large B-cell lymphoma (r/r LBCL) avo vakagamuchira nzira mbiri kana kupfuura dzekurapa kwesystemic. Izvi zvinosanganisira diffuse large B-cell ...Verenga zvakawanda»

Munguva pfupi yapfuura, murwere ane kenza yepancreatic yakakwira uye akange atadza kurapwa kakawanda akaonda bundu mushure mekugamuchira KD-496 CAR-T cell therapy, uye kusimbiswa kwekureruka kwakaramba kuripo mushure memazuva 180 mushure mekurapwa. Parizvino, kuchine miedzo yakawanda yekiriniki ye ...Verenga zvakawanda»

Musi wa16 Chikunguru, magazini yepamusoro-soro yepasi rose inonzi Nature Medicine yakaburitsa ruzivo rwekutsvagisa nezveSHR-A1904, mushonga unodzivirira zvirwere (ADC) unoshandiswa pakurapa claudin 18.2 (CLDN18.2), wekurapa kenza yemudumbu yakakwira kana kenza yemudumbu (GC/GEJC). Vatsvagurudzi vakaita ongororo yekutanga...Verenga zvakawanda»

Chikunguru 17, 2025 - Innovent Biologics yakazivisa kuti Nature Medicine yakaburitsa mhedzisiro yechidzidzo chekiriniki chePhase 1 cheIBI343, mushonga mutsva unodzivirira CLDN18.2 ADC, wekurapa advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. Chinyorwa ichi chiri muchirongwa chepasi rose chinotungamira...Verenga zvakawanda»